-
公开(公告)号：DE60130799T2
公开(公告)日：2008-07-17
申请号：DE60130799
申请日：2001-11-30
Applicant: CHILDRENS MEDICAL CENTER
Inventor： TRESTON ANTHONY , SHAH JAMSHED H , D AMATO ROBERT J , HUNSUCKER KIMBERLY A , ROUGAS JOHN , CONNER BARRY P , PRIBLUDA VICTOR , SWARTZ GLENN M
IPC: A61K31/445 , C07D401/04 , A61K31/454 , A61P1/16 , A61P1/18 , A61P3/02 , A61P3/10 , A61P5/00 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P13/08 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/04 , A61P19/06 , A61P25/00 , A61P27/02 , A61P27/06 , A61P27/10 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/22 , A61P33/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/02
-
公开(公告)号：DE69734290D1
公开(公告)日：2006-02-09
申请号：DE69734290
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
-
公开(公告)号：CA2341903A1
公开(公告)日：2000-03-02
申请号：CA2341903
申请日：1999-08-20
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: A61K31/00 , A61K31/404 , A61K31/65 , A61K31/775 , A61K31/787 , A61K35/36 , A61K38/17 , A61P27/02 , A61P35/00 , A61P43/00 , C08F2/32 , C08F20/28
Abstract: Compositions and methods of using melanin, or melanin-promoting compounds, f or inhibiting angiogenesis to treat angiogene- sis-dependent diseases, such as macular degeneration and cancer.
-
公开(公告)号：CA2514681A1
公开(公告)日：1998-05-14
申请号：CA2514681
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04
Abstract: The present invention comprises a group of compounds that effectively inhib it angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, thee compounds can be administered orally.
-
公开(公告)号：CA2262535A1
公开(公告)日：1998-02-12
申请号：CA2262535
申请日：1997-08-01
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J , KLAUBER NANCY
IPC: A61K45/00 , A61K31/335 , A61K31/336 , A61P15/18
Abstract: A method of inhibiting angiogenesis in a female mammal to regulate fertility comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. In addition, a method of inhibiting angiogenesis in a female mammal to treat a disease or condition of the reproductive tissue that is mediated by angiogenesis comprising administering to the female mammal an effective amount of an angiogenesis inhibiting compound. AGM-1470 is provided as such an angiogenesis inhibiting compound.
-
Patent Agency Ranking
公开(公告)号：DE69740095D1
公开(公告)日：2011-02-17
申请号：DE69740095
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: A61K31/44 , C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , A61P43/00 , C07D207/416 , C07D211/88 , C07D401/04
-
37.发明专利
公开(公告)号：NZ526683A
公开(公告)日：2008-03-28
申请号：NZ52668301
申请日：2001-11-30
Applicant: CHILDRENS MEDICAL CENTER
Inventor： TRESTON ANTHONY , SHAH JAMSHED H , D AMATO ROBERT J , HUNSUCKER KIMBERLY A , ROUGAS JOHN , CONNER BARRY P , PRIBLUDA VICTOR , SWARTZ GLENN M
IPC: C07D401/04 , A61K31/454 , A61P1/16 , A61P1/18 , A61P3/02 , A61P3/10 , A61P5/00 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P13/08 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/04 , A61P19/06 , A61P25/00 , A61P27/02 , A61P27/06 , A61P27/10 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/22 , A61P33/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/02
Abstract: A method of preparing S(-)-4-amino-thalidomide comprising: (a) contacting 3-nitrophthalic anhydride with S(-)-2-amino-glutarimide hydrobromide under conditions sufficient to form S(-)-4-nitro-thalidomide; and (b) reducing the S(-)-4-nitro-thalidomide under conditions sufficient to form S(-)-4-amino-thalidomide is disclosed; and similarly a method of preparing R(+)-4-amino-thalidomide comprising: (a) contacting 3-nitrophthalic anhydride with R(+)-2-amino-glutarimide hydrobromide under conditions sufficient to form R(+)-4-nitro-thalidomide; and (b) reducing the R(+)-4-nitro-thalidomide under conditions sufficient to form R(+)-4-amino-thalidomide is disclosed. These compounds are suitable for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration.
-
公开(公告)号：ES2290091T3
公开(公告)日：2008-02-16
申请号：ES01270117
申请日：2001-11-30
Applicant: CHILDRENS MEDICAL CENTER
Inventor： TRESTON ANTHONY , SHAH JAMSHED H , D AMATO ROBERT J , HUNSUCKER KIMBERLY A , ROUGAS JOHN , CONNER BARRY P
IPC: A61K31/445 , C07D401/04 , A61K31/454 , A61P1/16 , A61P1/18 , A61P3/02 , A61P3/10 , A61P5/00 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P13/08 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/04 , A61P19/06 , A61P25/00 , A61P27/02 , A61P27/06 , A61P27/10 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/22 , A61P33/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/02
Abstract: Un método para preparar S(-)-4-nitro-talidomida (5S) que comprende: poner en contacto anhídrido 3-nitroftálico (4) con hidrobromuro de S(-)-2-amino-glutarimida (3S) en la presencia de HOAc y DMF a 70-80º C durante 18-24 horas para formar S(-)-4-nitro-talidomida (5S).
-
39.发明专利
公开(公告)号：NZ336035A
公开(公告)日：2002-03-28
申请号：NZ33603597
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04 , C07D209/02 , C07D205/12
Abstract: A group of compounds that effectively inhibit angiogenesis is described. More specifically, the compounds comprise thalidomide or thalidomide precursors, analogues, metabolites and hydrolysis products, and antiinflammatory drugs, such as NSAIDs. The NSAIDs are selected from group consisting of aspirin, acetominophen, ibuprofen, esculetin, phenidone, quercetin, ketoprofen, nordihydroguiaretic acid (NDGA), sulindac, sulindac sulfone, sulindac sulfide, indomethacin, NS-398 (a cyclooxygenase-2 inhibitor), cyclooxygenase- 1 inhibitors, methylheptyl imidazole, furegrelate sodium, SKF525AHCL, thromboxane inhibitors, toradol, ecasa, salsalate, diflunisal, mefenamic acid, naproxen, naproxen sodium, floctafenine, meclofenamate, phenylbutazone, oxyphenbutazone, diclofenac, etodolac, fenoprofen, flufenamic acid, flurbiprofen, pirprofen, tolmetin, apazone, fenbufen, nabumetone, oxaprozin, piroxicam, salicylate, and tenoxicam. Importantly, these compounds can be administered orally.
-
公开(公告)号：HK1028874A1
公开(公告)日：2001-03-09
申请号：HK00103555
申请日：2000-06-14
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04 , A61K
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.023 seconds)
